Kate Raymond, DO
Family Medicine · Cartersville, GANPI 1093870479
Payments from drug & device makers
Across 92 payments — averaging $24.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$420
- Novo Nordisk$300
- AbbVie$279
- Johnson & Johnson$222
- GSK$203
- Lilly USA, LLC$128
- plus $746 from 13 others
What the payments were for
- Food & beverage$2,298100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $420 |
| Novo Nordisk | 16 | $300 |
| AbbVie | 13 | $279 |
| Johnson & Johnson | 5 | $222 |
| GSK | 12 | $203 |
| Lilly USA, LLC | 6 | $128 |
| Pfizer | 7 | $120 |
| Dexcom, Inc. | 3 | $96 |
| Amgen | 5 | $84 |
| Sumitomo Pharma America, Inc. | 1 | $73 |
| Boehringer Ingelheim | 3 | $67 |
| Shield Therapeutics Inc | 3 | $65 |
| Astellas Pharma US Inc | 4 | $60 |
| Abbott | 3 | $49 |
| Bayer | 2 | $45 |
| Sanofi-aventis U.S. LLC | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$237
- BREZTRI AEROSPHERE$127
- XARELTO$125
How this compares
$2,298 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $171,213 |
| FarxigaDapagliflozin Propanediol | 108 | $86,809 |
| MounjaroTirzepatide | 78 | $82,787 |
| ProliaDenosumab | 38 | $64,853 |
| JardianceEmpagliflozin | 66 | $61,453 |
| EliquisApixaban | 45 | $53,238 |
| RybelsusSemaglutide | 22 | $41,769 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $35,087 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $34,402 |
| TrulicityDulaglutide | 21 | $33,119 |
| MyrbetriqMirabegron | 43 | $28,188 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $27,292 |
| XareltoRivaroxaban | 15 | $24,188 |
| LinzessLinaclotide | 21 | $23,816 |
| VraylarCariprazine Hcl | 15 | $21,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $300 | $212,983154 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $420 | $124,206168 claims |
| Lilly USA, LLCMounjaro, Trulicity | $128 | $115,90699 claims |
| AmgenProlia | $84 | $64,85338 claims |
| Boehringer IngelheimJardiance | $67 | $61,45366 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arnuity Ellipta | $203 | $58,096102 claims |
| PfizerEliquis | $120 | $53,23845 claims |
| AbbVieLinzess, Vraylar, Synthroid | $279 | $48,85375 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $28,18843 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $30 | $27,29222 claims |
| Johnson & JohnsonXarelto | $222 | $24,18815 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $73 | $14,29016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Cartersville
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.